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Prior to the advent of effective cytomegalovirus (CMV)-specific therapy, Henry H. Balfour likened CMV to 
the troll in the story “Three Billy Goats Gruff,” who threatened to devour patients with organ failure who 
sought greener pastures across the bridge of transplantation (1). Nearly 40 years later, CMV continues to 
plague allograft recipients, of whom lung allograft recipients are the most affected (2). This increased CMV 
burden in lung allograft recipients may result from CMV tropism for lung tissue and relatively more intensive 
immunosuppression (3). CMV causes morbidity and mortality both directly and indirectly through increased 
rates of non-CMV infection and chronic lung allograft dysfunction (CLAD) (2). CMV can lead to graft 
dysfunction through multiple mechanisms, including direct cytotoxicity; CMV-specific T, B, and NK cell 
targeting of infected cells; and heterologous immune responses promoting allo- or auto-immunity.  
 
Given the burden of CMV disease in lung transplant recipients, consensus guidelines recommend anti-
CMV prophylaxis (2). Yet despite 3-6 months of prophylaxis, CMV replication detected in bronchoalveolar 
lavage fluid is associated with nearly a 2-fold increase in the risk of CLAD (4). A multicenter randomized 
trial showed decreased frequency and severity of CMV infection in recipients treated with 12-months, as 
opposed to 3-months, of post-transplant anti-CMV prophylaxis (5). Some centers, including ours, have 
even advocated for CMV prophylaxis beyond 12 months (6). However, up to half of these lung transplant 
recipients will require discontinuation of indefinite CMV prophylaxis, mostly due to drug toxicities, which 
include leukopenia.  
 
Leukopenia requiring medication adjustment is more common in lung allograft recipients with telomere 
dysfunction (7). Telomere dysfunction is well described as a cause of idiopathic pulmonary fibrosis (IPF), 
and shortened telomeres have also been linked with other lung transplant indications such as chronic 
obstructive pulmonary disease (8). It is thus not surprising that telomeropathies are enriched among lung 
allograft recipients. In this issue of the Journal, Popescu et al. report that the same lung transplant 
recipients likely to have CMV prophylaxis discontinued secondary to telomere-related leukopenia may also 
be at greatest risk for uncontrolled CMV infection (9). In this cohort, IPF patients with short peripheral blood 
leukocyte telomeres had a 9-fold higher risk of CMV relapse compared to a matched control cohort of non-
IPF lung transplant recipients, despite receiving similar durations of CMV prophylaxis. IPF patients with 
normal telomere length did not appear at increased CMV risk. 
 
The authors hypothesized that the observed increase in CMV disease may reflect defects in T cell-
mediated control of CMV replication. Examining lymphocytes isolated from subjects at the time of viremia, 
they found that T cells from individuals with short telomeres proliferated less, made fewer cytokines, and 
had less induction of the transcription factor, T-bet, when stimulated with CMV peptides. Such impairments 
have been previously linked with failure to control CMV infection (9), but exactly how telomere shortening 
leads to this global T cell impairment remains uncertain. As illustrated in Figure 1, telomere shortening has 
been linked to the related but distinct processes of T cell exhaustion (loss of functional activity), 
senescence (cell cycle arrest), and apoptosis (programmed cell death) (10, 11). While this study did not 
examine markers of T cell senescence, reports that T-bet expression is positively correlated with 
senescence markers might argue against senescence as the main mechanism linking telomere 
dysfunction and impaired CMV immunity (12). At the same time, chronic CMV antigen stimulation could 
directly cause T cell exhaustion with associated decreases in T-bet induction and impairment of telomerase 
expression.  
 
Figure 1: During initial infection, T cells respond to CMV antigen stimulation by 
proliferating. Absent defects in telomerase-complex proteins, telomerase may maintain 
telomere lengths in these T cells. However, T cell proliferation, functional and 
telomerase activity start to diminish in the face of chronic antigen exposure and T cells 
progress towards phenotypes of exhaustion, senescence, or apoptosis. These 
phenotypes can cause or be caused by telomere shortening. 
 
These are interesting findings, which diverge somewhat from prior work. An increased risk of CMV infection 
was not observed in recipients with short telomeres in the two prior cohort studies (13, 14). At our center, 
recipients with short telomeres had increased rates of leukopenia requiring medication adjustment again 
did not have increased rates of CMV infection (7). Indeed, impairment of CLAD-free survival was more 
associated with short donor, rather than recipient, telomeres. Within the allograft, telomerase activity could 
be important for regenerating airways damaged by transplant-related injury, and, interestingly, CMV 
infection increases rates of allograft cell turnover more than other infections in lung allograft recipients (15). 
Generalizability can be a challenge in interpreting lung transplant studies because recipient populations 
and treatment protocols vary widely between centers. Such differences may explain discrepancies 
between the present findings and other cohorts. In this article, 71% of the patients with IPF had telomere 
lengths below the 10th percentile, which is substantially higher than the 32% of IPF lung transplant 
recipients in the cohort described at UT Southwestern (14). The high incidence of biopsy-proven end-organ 
CMV disease in 17 of 84 subjects was also not reported in other cohorts.  
 
The collective experience caring for lung transplant recipients with short telomeres suggests that their 
clinical courses likely differ from recipients with normal telomere length because of unique telomere-related 
impacts on an individual’s immune system, consistent with the well-established effects of telomeropathies 
outside of the context of lung transplantation. Measuring telomere length in potential lung transplant 
candidates has the potential to aid in evaluating candidacy, selecting grafts by CMV serostatus, guiding 
immunosuppression and CMV prophylaxis choices, and assessing risks for CMV infection, primary graft 
dysfunction, CLAD, and death. Still, transplant candidates with short telomeres are likely better off getting 
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a CMV+ graft than no graft because the risk of CMV-related complications remains manageable. At the 
same time, short telomeres do not account for the entirety of CMV risk, to which impaired antibody, T cell, 
and NK cell responses are important contributors. In summary, given the variable manifestations of 
telomere dysfunction observed across centers, further studies will be needed to understand how telomere 
length measurements should be incorporated into pre- or post-transplant management protocols. 
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